Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples